Front-line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression control.
Huang SH, Huang AC, Wang CC, Chang WC, Liu CY, Pavlidis S, Ko HW, Chung FT, Hsu PC, Guo YK, Kuo CS, Yang CT. Front-line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression control. Thorac Cancer. 2019 12; 10(12):2274-2281.